Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada

Praesidio Health, a wholly-owned subsidiary of Isracann Biosciences Inc. ISCNF IPOT A, has completed the natural product number (NPN) submissions to Health Canada for its first formulations.

Praesidio Health is a Canadian medical research company that develops and validates natural health products (“NHPs”) using an evidence-based process has submitted all first-round product formulations to Health Canada for review and approval as natural health products under a class 2 NPN submission. It is anticipated that approvals will be expedited due to the fundamental natural ingredient makeup of the formulations.

Isracann board member Dr. George Vrabec, MD FRCSC (Urol.) an experienced principal investigator of numerous clinical trials stated, “Our recent NPN submission to Health Canada moves us closer to credentializing natural health as agents of choice for conditions that may be incompletely treated by conventional pharmaceutical drugs. The application of our NPN's in these, usually chronic conditions including post-viral syndrome, low libido, lower urinary tract symptoms, and generalized anxiety, when validated, may move these into a preferred first line of care in the primary care setting.”

Get Started

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Get Started

Company management believes that because of the Praesidio acquisition, the outlook for near-term revenue generation is increasingly positive with current strategic goals targeting completion of initial product formulations in readiness for store shelves in both Canada and the USA during Q4 2022.

Company CEO & president Phil Floucault states, “Our proprietary formulations are designed to be unique in the marketplace, utilizing the latest studies in nutraceutical science. In keeping with our DNA to use evidenced-based practices, once the formulations are approved by Health Canada, we plan to test each formulation via third-party consumer studies and advance towards commercialization as quickly as possible. We are also advancing our CMO partnerships in both Canada and the US to ensure our manufacturing and supply chain needs are fulfilled in the near term. We look forward to a fast track to sales in 2022.”

Related News

Isracann Biosciences Acquires Praesidio Health And Appoints Natural Health Products Officers